Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00815035 · ClinicalTrials.gov registry record · Phase 2
Oral Immunotherapy (OIT) for Peanut Allergy
A Phase 2 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00815035 is a Phase 2 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 16 participants.
The verdict
NCT00815035, a Phase 2 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
Peanut allergy is known to cause severe anaphylactic reactions.The goal of this proposal is to produce a new treatment that would benefit subjects who have peanut allergy by lowering the risk of anaphylactic reactions (desensitization), and changing the peanut-specific immune response in subjects who have peanut allergy (tolerance).
Interventions
- DRUG Placebo
- DRUG Peanut OIT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-04 |
| Est. Completion | 2016-12-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00815035
The ClinicalTrials.gov registry entry for NCT00815035 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00815035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00815035 about?
NCT00815035 is a clinical study titled "Oral Immunotherapy (OIT) for Peanut Allergy". Peanut allergy is known to cause severe anaphylactic reactions.The goal of this proposal is to produce a new treatment that would benefit subjects who have peanut allergy by lowering the risk of anaphylactic reactions (desensitization), and changing the peanut-specific immune response in subjects wh...
What is the current status of trial NCT00815035?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2009-04. Estimated completion is 2016-12-12.
What interventions are being tested in trial NCT00815035?
The interventions under investigation include: Placebo (DRUG), Peanut OIT (DRUG).
Who is sponsoring clinical trial NCT00815035?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.